Recent Updates
Recently added Catalysts
GILD Neutral Sentiment

Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences

Friday, October 30, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Gilead Sciences announced that its executives will present at several upcoming investor conferences. These include the Wolfe Research Healthcare Conference on November 10, the UBS Global Biopharma Conference on November 17, and the Citi's Global Healthcare Conference on December 1. This engagement aims to connect with investors and discuss company updates.

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
Zimberelimab
Phase 3 · Non-small Cell Lung Cancer

Full Press Release Details

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:Wolfe Research Healthcare Conference on Tuesday, November 10 at 11:20 AM Eastern TimeUBS Global Biopharma Conference on Tuesday, November 17 at 10:00 AM Greenwich Mean TimeJefferies Global Healthcare Conference on Tuesday, November 17 at 2:30 PM Greenwich Mean TimeCiti’s Global Healthcare Conference on Tuesday, December 1 at 11:00 A

Frequently Asked Questions

When will Gilead present at investor conferences?

Gilead will present at conferences on November 10, November 17, and December 1.

Which conferences will Gilead attend?

Gilead will attend the Wolfe, UBS, Jefferies, and Citi conferences.

What is the purpose of Gilead's presentations?

The presentations aim to engage with investors and discuss company developments.

What time will Gilead present at the Wolfe Conference?

Gilead will present at the Wolfe Research Healthcare Conference at 11:20 AM ET.

ShareAdd on Google
Tags: GILD Gilead Sciences investor conferences biopharma events healthcare conference
Last updated: Oct 30, 2026

Biotech snapshot

Cash runway
$6437M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ZimberelimabPhase 3
Non-small Cell Lung Cancer →

Catalyst track record

+36%
best trade around GILD's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for GILD.

See every catalyst's timing & PoA →